CD44 and central nervous system cancer: Altogether, our mRNA analysis in vitro and in vivo show that myeloid-cKO of CD44 severely hampers MMP9 upregulation in glioma-associated myeloid cells, and additionally affects levels of the pro-inflammatory cytokines.